Ischemic Heart Disease: A Secondary Prevention Trial Using Clofibrate (Atromid-S)

  • M. F. Oliver
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 26)


When the initial clinical trials of clofibrate had been completed and when it seemed fairly certain that this drug had no toxic effects and only minimal side effects, a formal trial was established to determine whether reduction of elevated serum cholesterol levels would be associated with a lower morbidity and mortality rate in patients with established ischemic heart disease. This was begun in 1965 and was completed in 1970.


Placebo Group Ischemic Heart Disease Serum Cholesterol Level Secondary Prevention Trial Formal Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Report by a Research Committee of the Scottish Society of Physicians, “Ischaemic Heart Disease: A Secondary Prevention Trial using Clofibrate.” Brit. Med. J. 4: 775 (1971).CrossRefGoogle Scholar
  2. 2.
    Five year study by a group of physicians of the Newcastle upon Tyne region, “Trial of Clofibrate in the Treatment of Ischaemic Heasrt Disease.” Brit. Med. J. 4: 767 (1971).CrossRefGoogle Scholar
  3. 3.
    Dewar, H. A. and M. F. Oliver. A Joint Commentary on the Newcastle and Scottish Trials. Brit. Med. J. 4: 784 (1971).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • M. F. Oliver
    • 1
  1. 1.Department of CardiologyRoyal InfirmaryEdinburghScotland

Personalised recommendations